We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · February 28, 2021

Good Outcomes Following Reverse Switching From CT-P13 to Originator Infliximab in IBD

Inflammatory Bowel Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
Inflamm. Bowel Dis. 2021 Feb 04;[EPub Ahead of Print], S Mahmmod, JPD Schultheiss, AA van Bodegraven, G Dijkstra, LPL Gilissen, F Hoentjen, MWMD Lutgens, N Mahmmod, AE van der Meulen-de Jong, LJT Smits, ACITL Tan, B Oldenburg, HH Fidder

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading